Clinical Trial Search

Primary: Healing Defined as a Decrease in Ulcer Area by at Least 25% of the Initial Area — 24; 78 percentage of healed ulcers — p=0.05

Primary: Percentage of Participants With a Psoriasis Area and Severity Index (PASI)75 Response at Week 16 — 33.33; 64.44; 66.29; 74.42 Percentage of participants — p=0.001

Primary: Complete Hematologic Response — 16 participants

Primary: Mean Level of Diindolylmethane in Prostate Tissue After Treatment — 14.2 ng/g

Primary: Dose Limiting Toxicity of Bendamustine Hydrochloride and Lenalidomide in Combination With Dexamethasone (Phase I) — 0; 1; 0; 0 Dose Limiting Toxic Events

Primary: Status of FAS Ligand in Pre-chemotherapy Sample — 7; 5; 1; 1 participants

Primary: Bone Mineral Density — 0.01; -0.11 g/cm^2 — p=0.10

Primary: Percentage of Parts 2 and 3 Participants Who Achieved American College of Rheumatology Response of 20 (ACR20) — 46; 27 percentage of participants

Primary: Disease Response — 10; 10; 19; 10 patient

Primary: Overall Response Rate (Defined as Partial Remission or Better) to 3 Months of Treatment With Erlotinib — 0 percentage of participants

Primary: Overall Response Rate (PR+nCR+CR) — 34.5 percentage of participants

Primary: The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque-type Psoriasis With Respect to PASI 75…

Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1

Primary: Per-subject Diagnostic Yield of the PillCam Platform With the CD Capsule Within the Terminal Ileum and Colon as Compared to the Ileocolonoscopy Diagnostic Yield Within…

Primary: Median Progression Free Survival — 10.1 weeks